EUCTR2016-002688-32-HU进行中（未招募）1 期
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared with Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Patients with Influenza at High Risk of Influenza Complications
Shionogi Ltd.0 个研究点目标入组 2,157 人开始时间: 2017年5月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 2,157
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients who fulfill all of the following criteria will be included in the study:
- •1. Patients or their legal guardians who provide written informed consent to participate in the study on a voluntary basis. For adolescent patients, informed consent/assent of voluntary participation should be obtained in accordance with local requirements.
- •2. Male or female patients = 12 years at the time of signing the informed consent/assent form.
- •3. Patients with diagnosis of influenza confirmed by all of the following:
- •a. Fever = 38ºC (axillary) during the predose examinations or > 4 hours after dosing of antipyretics if they were taken
- •b. At least 1 each of the following general and respiratory symptoms associated with influenza (excluding those that are chronic and existed in the 30 days prior to the influenza episode) is present with a severity of moderate or greater:
- •i. General symptoms (headache, feverishness or chills, muscle or joint pain, or fatigue)
- •ii. Respiratory symptoms (cough, sore throat, or nasal congestion)
- •4. The time interval between the onset of symptoms and the predose examinations (Screening) is 48 hours or less. The onset of symptoms is defined as either:
- •a. Time of the first increase in body temperature (an increase of at least 1ºC from normal body temperature)
- •b. Time when the patient experiences at least 1 new general or respiratory symptom
- •5. If a women of childbearing potential, agrees to use a highly effective method of contraception for 3 months after the first dose of S-033188 or oseltamivir.
- •6. Patients will be considered at high risk of influenza complications due to the presence of at least 1 of the following inclusion criteria:
- •a. Asthma or chronic lung disease (such as chronic obstructive pulmonary disease or cystic fibrosis)
- •b. Endocrine disorders (including diabetes mellitus)
- •c. Residents of long-term care facilities (eg, nursing homes)
- •d. Compromised immune system (including patients receiving corticosteroids not exceeding 20 mg of prednisolone or equivalent, and patients being treated for human immunodeficiency virus (HIV) infection with a CD4 count > 350 cells/mm3 within the last 6 months)
- •e. Neurological and neurodevelopmental disorders (including disorders of the brain, spinal cord, peripheral nerve, and muscle, eg, cerebral palsy, epilepsy [seizure disorders], stroke, muscular dystrophy, or spinal cord injury)
- •f. Heart disease (such as congenital heart disease, congestive heart failure, or coronary artery disease), excluding hypertension without any other heart-related symptoms
- •g. Adults aged = 65 years
- •h. American Indians and Alaskan Natives
- •i. Blood disorders (such as sickle cell disease)
- •j. Metabolic disorders (such as inherited metabolic disorders and mitochondrial disorders)
- •k. Morbid obesity (body mass index = 40)
- •l. Women who are within 2 weeks postpartum and are not breastfeeding
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 863
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 863
排除标准
- •Patients who meet any of the following criteria will be excluded from the study:
- •1. Patients with severe influenza virus infection requiring inpatient treatment.
- •2. Patients with known allergy to oseltamivir (Tamiflu®).
- •3. Patients unable to swallow tablets or capsules.
- •4. Patients who have previously received S-033188.
- •5. Patients weighing < 40 kg.
- •6. Patients who have been exposed to an investigational drug within 30 days prior to the predose examinations.
- •7. Women who are pregnant, breastfeeding, or have a positive pregnancy test at the predose examinations. The following female patients who have documentation of either a or b below do not need to undergo a pregnancy test at the predose examinations:
- •a. Postmenopausal women (defined as cessation of regular menstrual periods for 2 years or more and confirmed by a follicle-stimulating hormone test)
- •b. Women who are surgically sterile by hysterectomy, bilateral oophorectomy, or tubal ligation
- •8. Patients with concurrent infections at the predose examinations requiring systemic antimicrobial therapy.
- •9. Patients with liver disease associated with hepatic impairment.
- •10. Patients with cancer within the last 5 years (unless nonmelanoma skin cancer).
- •11. Patients with untreated HIV infection or treated HIV infection with a CD4 count below 350 cells/mm3 in the last 6 months.
- •12. Patients with untreated HIV infection or treated HIV infection with an unknown CD4 count or a CD4 count below 350 cells/mm3 in the last 6 months.
- •13. Patients exceeding 20 mg of prednisolone or equivalent dose of chronic systemic corticosteroids.
- •14. Patients who have received peramivir, laninamivir, oseltamivir, zanamivir, rimantadine, umifenovir or amantadine within 30 days prior to the predose examinations.
- •15. Patients who have received an investigational monoclonal antibody for a viral disease in the last year.
- •16. Patients with current creatinine clearance = 60 mL/min (=30 mL/min in Japan).
- •17. Patients with hereditary galactose intolerance, Lapp lactase deficiency, or glucose-galactose intolerance.
- •18. Pediatric patients in countries where national legislation prohibits the conduct of studies with a placebo arm in pediatrics.
- •19. Patients who, in the opinion of the investigator, would be unlikely to comply with required study visits, self-assessments, and interventions.
研究者
相似试验
进行中（未招募）
1 期
A clinical trial which compares the effectiveness and safety of a not yet approved drug, called S-033188, versus placebo, and versus an approved drug (Oseltamivir) for 5 Days in Patients with Influenza at High Risk of Influenza ComplicationsInfluenzaEUCTR2016-002688-32-BGShionogi Ltd.2,157
进行中（未招募）
1 期
A clinical trial to investigate the safety and effectiveness of MMX Mesalamine/mesalazine in Children and Adolescents aged 5-17 years who have mild to moderate Ulcerative ColitisMild to Moderate Ulcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2013-001744-65-HUShire Devlopment LLC107
进行中（未招募）
1 期
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Tigecycline Versus Comparator (Clindamycin or Vancomycin) for the Treatment of Complicated Skin and Skin Structure Infections, Including Those due to MRSA, in Pediatric Subjects Ages 8 to 17 Years OldComplicated skin and skin structure infection (cSSSI) with or without methicillin-resistant Staphylococcus aureus (MRSA)MedDRA version: 9.1 Level: LLT Classification code 10040872 Term: Skin infectionMedDRA version: 9.1 Level: LLT Classification code 10066409 Term: Staphylococcal skin infectionMedDRA version: 9.1 Level: LLT Classification code 10066412 Term: Staphylococcal aureus skin infectionEUCTR2008-001936-11-GBWyeth Pharmaceuticals Inc., Acting through its division Wyeth Research, a Pfizer Company400
进行中（未招募）
1 期
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Tigecycline Versus Comparator (Clindamycin or Vancomycin) for the Treatment of Complicated Skin and Skin Structure Infections, Including Those due to MRSA, in Pediatric Subjects Ages 8 to 17 Years OldComplicated skin and skin structure infection (cSSSI) with or without methicillin-resistant Staphylococcus aureus (MRSA)MedDRA version: 9.1Level: LLTClassification code 10040872Term: Skin infectionMedDRA version: 9.1Level: LLTClassification code 10066409Term: Staphylococcal skin infectionMedDRA version: 9.1Level: LLTClassification code 10066412Term: Staphylococcal aureus skin infectionEUCTR2008-001936-11-BEWyeth Pharmaceuticals Inc., acting through its division Wyeth Research, a Pfizer Company400
进行中（未招募）
不适用
A Phase 3, Multicenter, Randomized, Double-blind Study Comparing the Safety and Efficacy of ABT-874 to Methotrexate in Subjects with Moderate to Severe Chronic Plaque Psoriasis.Moderate to severe chronic plaque psoriasisMedDRA version: 9.1Level: LLTClassification code 10037153Term: PsoriasisEUCTR2007-004687-47-DKAbbott GmbH & Co. K.G.250